This study is in progress, not accepting new patients
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
Summary
- Eligibility
- for people ages 18-75 (full criteria)
- Location
- at UCSD UCSF
- Dates
- study startedstudy ends around
- Principal Investigator
- by Kendall Beck (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Kendall Beck (ucsf)
Dr. Kendall Beck is a gastroenterologist who cares for patients with general diseases of the stomach or intestines, inflammatory bowel disease and short bowel syndrome. She also performs endoscopic procedures. Beck earned her medical degree from McGovern Medical School at the University of Texas Health Science Center at Houston.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AbbVie
- ID
- NCT03345823
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 747 study participants
- Last Updated